

Primary Sclerosing Cholangitis Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/PD7DA25A8924EN.html>

Date: February 2022

Pages: 110

Price: US\$ 3,250.00 (Single User License)

ID: PD7DA25A8924EN

Abstracts

Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases. The disease is characterized by inflammation and thickening of the bile ducts. This impedes bile flow and may lead to other liver diseases. Primary sclerosing cholangitis (PSC) is treated in addition to PSC and avoids other liver diseases. Available options are liver transplantation, UDCA drugs, and PSC drugs, each with advantages and disadvantages in cost and efficacy.

This report contains market size and forecasts of Primary Sclerosing Cholangitis Treatment in Global, including the following market information:

Global Primary Sclerosing Cholangitis Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Primary Sclerosing Cholangitis Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Liver Transplantation Operation Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Primary Sclerosing Cholangitis Treatment include

Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma and Mitsubishi Tanabe Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Sclerosing Cholangitis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Primary Sclerosing Cholangitis Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Primary Sclerosing Cholangitis Treatment Market Segment Percentages, by Type, 2021 (%)

Liver Transplantation Operation

UDCA Drugs

PSC Drugs

Global Primary Sclerosing Cholangitis Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Primary Sclerosing Cholangitis Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinics

Other

Global Primary Sclerosing Cholangitis Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Primary Sclerosing Cholangitis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Primary Sclerosing Cholangitis Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Primary Sclerosing Cholangitis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Allergan

Glenmark

Impax Laboratories

Mylan

Teva Pharmaceuticals

Dr. Falk Pharma

Daewoong Pharmaceutical

Epic Pharma

Mitsubishi Tanabe Pharma

Lannett

Bruschettini

Shanghai Pharma

Grindeks

Acorda Therapeutics

Gilead Sciences

Intercept Pharmaceuticals

Shire Plc

NGM Biopharmaceuticals

Conatus Pharmaceuticals

Durect Corporation

Sirnaomics

Shenzhen HighTide Biopharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Primary Sclerosing Cholangitis Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Primary Sclerosing Cholangitis Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL PRIMARY SCLEROSING CHOLANGITIS TREATMENT OVERALL MARKET SIZE

- 2.1 Global Primary Sclerosing Cholangitis Treatment Market Size: 2021 VS 2028
- 2.2 Global Primary Sclerosing Cholangitis Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Primary Sclerosing Cholangitis Treatment Players in Global Market
- 3.2 Top Global Primary Sclerosing Cholangitis Treatment Companies Ranked by Revenue
- 3.3 Global Primary Sclerosing Cholangitis Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Primary Sclerosing Cholangitis Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Primary Sclerosing Cholangitis Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Primary Sclerosing Cholangitis Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Primary Sclerosing Cholangitis Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Primary Sclerosing Cholangitis Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Primary Sclerosing Cholangitis Treatment Market Size Markets, 2021 & 2028

4.1.2 Liver Transplantation Operation

4.1.3 UDCA Drugs

4.1.4 PSC Drugs

4.2 By Type - Global Primary Sclerosing Cholangitis Treatment Revenue & Forecasts

4.2.1 By Type - Global Primary Sclerosing Cholangitis Treatment Revenue, 2017-2022

4.2.2 By Type - Global Primary Sclerosing Cholangitis Treatment Revenue, 2023-2028

4.2.3 By Type - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Primary Sclerosing Cholangitis Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinics

5.1.4 Other

5.2 By Application - Global Primary Sclerosing Cholangitis Treatment Revenue & Forecasts

5.2.1 By Application - Global Primary Sclerosing Cholangitis Treatment Revenue, 2017-2022

5.2.2 By Application - Global Primary Sclerosing Cholangitis Treatment Revenue, 2023-2028

5.2.3 By Application - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Primary Sclerosing Cholangitis Treatment Market Size, 2021 & 2028

6.2 By Region - Global Primary Sclerosing Cholangitis Treatment Revenue & Forecasts

6.2.1 By Region - Global Primary Sclerosing Cholangitis Treatment Revenue, 2017-2022

6.2.2 By Region - Global Primary Sclerosing Cholangitis Treatment Revenue, 2023-2028

6.2.3 By Region - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Primary Sclerosing Cholangitis Treatment Revenue, 2017-2028

6.3.2 US Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.3.3 Canada Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.3.4 Mexico Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Primary Sclerosing Cholangitis Treatment Revenue, 2017-2028

6.4.2 Germany Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.4.3 France Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.4.4 U.K. Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.4.5 Italy Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.4.6 Russia Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.4.8 Benelux Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Primary Sclerosing Cholangitis Treatment Revenue, 2017-2028

6.5.2 China Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.5.3 Japan Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.5.4 South Korea Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.5.6 India Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Primary Sclerosing Cholangitis Treatment Revenue, 2017-2028

6.6.2 Brazil Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.6.3 Argentina Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue, 2017-2028

- 6.7.2 Turkey Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028
- 6.7.3 Israel Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028
- 6.7.4 Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028
- 6.7.5 UAE Primary Sclerosing Cholangitis Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Allergan

- 7.1.1 Allergan Corporate Summary
- 7.1.2 Allergan Business Overview
- 7.1.3 Allergan Primary Sclerosing Cholangitis Treatment Major Product Offerings
- 7.1.4 Allergan Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
- 7.1.5 Allergan Key News

7.2 Glenmark

- 7.2.1 Glenmark Corporate Summary
- 7.2.2 Glenmark Business Overview
- 7.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Major Product Offerings
- 7.2.4 Glenmark Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
- 7.2.5 Glenmark Key News

7.3 Impax Laboratories

- 7.3.1 Impax Laboratories Corporate Summary
- 7.3.2 Impax Laboratories Business Overview
- 7.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Major Product Offerings
- 7.3.4 Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
- 7.3.5 Impax Laboratories Key News

7.4 Mylan

- 7.4.1 Mylan Corporate Summary
- 7.4.2 Mylan Business Overview
- 7.4.3 Mylan Primary Sclerosing Cholangitis Treatment Major Product Offerings
- 7.4.4 Mylan Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
- 7.4.5 Mylan Key News

7.5 Teva Pharmaceuticals

- 7.5.1 Teva Pharmaceuticals Corporate Summary
- 7.5.2 Teva Pharmaceuticals Business Overview

7.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.5.4 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.5.5 Teva Pharmaceuticals Key News

7.6 Dr. Falk Pharma

7.6.1 Dr. Falk Pharma Corporate Summary

7.6.2 Dr. Falk Pharma Business Overview

7.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.6.4 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.6.5 Dr. Falk Pharma Key News

7.7 Daewoong Pharmaceutical

7.7.1 Daewoong Pharmaceutical Corporate Summary

7.7.2 Daewoong Pharmaceutical Business Overview

7.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.7.4 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.7.5 Daewoong Pharmaceutical Key News

7.8 Epic Pharma

7.8.1 Epic Pharma Corporate Summary

7.8.2 Epic Pharma Business Overview

7.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.8.4 Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.8.5 Epic Pharma Key News

7.9 Mitsubishi Tanabe Pharma

7.9.1 Mitsubishi Tanabe Pharma Corporate Summary

7.9.2 Mitsubishi Tanabe Pharma Business Overview

7.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.9.4 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.9.5 Mitsubishi Tanabe Pharma Key News

7.10 Lannett

7.10.1 Lannett Corporate Summary

7.10.2 Lannett Business Overview

- 7.10.3 Lannett Primary Sclerosing Cholangitis Treatment Major Product Offerings
- 7.10.4 Lannett Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
- 7.10.5 Lannett Key News
- 7.11 Bruschettini
 - 7.11.1 Bruschettini Corporate Summary
 - 7.11.2 Bruschettini Business Overview
 - 7.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Major Product Offerings
 - 7.11.4 Bruschettini Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
 - 7.11.5 Bruschettini Key News
- 7.12 Shanghai Pharma
 - 7.12.1 Shanghai Pharma Corporate Summary
 - 7.12.2 Shanghai Pharma Business Overview
 - 7.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Major Product Offerings
 - 7.12.4 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
 - 7.12.5 Shanghai Pharma Key News
- 7.13 Grindeks
 - 7.13.1 Grindeks Corporate Summary
 - 7.13.2 Grindeks Business Overview
 - 7.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Major Product Offerings
 - 7.13.4 Grindeks Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
 - 7.13.5 Grindeks Key News
- 7.14 Acorda Therapeutics
 - 7.14.1 Acorda Therapeutics Corporate Summary
 - 7.14.2 Acorda Therapeutics Business Overview
 - 7.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Major Product Offerings
 - 7.14.4 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)
 - 7.14.5 Acorda Therapeutics Key News
- 7.15 Gilead Sciences
 - 7.15.1 Gilead Sciences Corporate Summary
 - 7.15.2 Gilead Sciences Business Overview
 - 7.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.15.4 Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.15.5 Gilead Sciences Key News

7.16 Intercept Pharmaceuticals

7.16.1 Intercept Pharmaceuticals Corporate Summary

7.16.2 Intercept Pharmaceuticals Business Overview

7.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.16.4 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.16.5 Intercept Pharmaceuticals Key News

7.17 Shire Plc

7.17.1 Shire Plc Corporate Summary

7.17.2 Shire Plc Business Overview

7.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.17.4 Shire Plc Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.17.5 Shire Plc Key News

7.18 NGM Biopharmaceuticals

7.18.1 NGM Biopharmaceuticals Corporate Summary

7.18.2 NGM Biopharmaceuticals Business Overview

7.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.18.4 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.18.5 NGM Biopharmaceuticals Key News

7.19 Conatus Pharmaceuticals

7.19.1 Conatus Pharmaceuticals Corporate Summary

7.19.2 Conatus Pharmaceuticals Business Overview

7.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.19.4 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.19.5 Conatus Pharmaceuticals Key News

7.20 Durect Corporation

7.20.1 Durect Corporation Corporate Summary

7.20.2 Durect Corporation Business Overview

7.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.20.4 Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.20.5 Durect Corporation Key News

7.21 Sirnaomics

7.21.1 Sirnaomics Corporate Summary

7.21.2 Sirnaomics Business Overview

7.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.21.4 Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.21.5 Sirnaomics Key News

7.22 Shenzhen HighTide Biopharmaceuticals

7.22.1 Shenzhen HighTide Biopharmaceuticals Corporate Summary

7.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview

7.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Major Product Offerings

7.22.4 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue in Global Market (2017-2022)

7.22.5 Shenzhen HighTide Biopharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Primary Sclerosing Cholangitis Treatment Market Opportunities & Trends in Global Market

Table 2. Primary Sclerosing Cholangitis Treatment Market Drivers in Global Market

Table 3. Primary Sclerosing Cholangitis Treatment Market Restraints in Global Market

Table 4. Key Players of Primary Sclerosing Cholangitis Treatment in Global Market

Table 5. Top Primary Sclerosing Cholangitis Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Primary Sclerosing Cholangitis Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Primary Sclerosing Cholangitis Treatment Product Type

Table 9. List of Global Tier 1 Primary Sclerosing Cholangitis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Primary Sclerosing Cholangitis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Primary Sclerosing Cholangitis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Primary Sclerosing Cholangitis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Primary Sclerosing Cholangitis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Primary Sclerosing Cholangitis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Primary Sclerosing Cholangitis Treatment

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Primary Sclerosing Cholangitis Treatment

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Allergan Corporate Summary

Table 31. Allergan Primary Sclerosing Cholangitis Treatment Product Offerings

Table 32. Allergan Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Glenmark Corporate Summary

Table 34. Glenmark Primary Sclerosing Cholangitis Treatment Product Offerings

Table 35. Glenmark Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Impax Laboratories Corporate Summary

Table 37. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product Offerings

Table 38. Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Mylan Corporate Summary

Table 40. Mylan Primary Sclerosing Cholangitis Treatment Product Offerings

Table 41. Mylan Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Teva Pharmaceuticals Corporate Summary

Table 43. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings

Table 44. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Dr. Falk Pharma Corporate Summary

Table 46. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product Offerings

Table 47. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Daewoong Pharmaceutical Corporate Summary

Table 49. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product Offerings

Table 50. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Epic Pharma Corporate Summary

Table 52. Epic Pharma Primary Sclerosing Cholangitis Treatment Product Offerings

Table 53. Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Mitsubishi Tanabe Pharma Corporate Summary

Table 55. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product Offerings

Table 56. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Lannett Corporate Summary

Table 58. Lannett Primary Sclerosing Cholangitis Treatment Product Offerings

Table 59. Lannett Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. Bruschettini Corporate Summary

Table 61. Bruschettini Primary Sclerosing Cholangitis Treatment Product Offerings

Table 62. Bruschettini Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. Shanghai Pharma Corporate Summary

Table 64. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product Offerings

Table 65. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 66. Grindeks Corporate Summary

Table 67. Grindeks Primary Sclerosing Cholangitis Treatment Product Offerings

Table 68. Grindeks Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 69. Acorda Therapeutics Corporate Summary

Table 70. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product

Offerings

Table 71. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 72. Gilead Sciences Corporate Summary

Table 73. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product Offerings

Table 74. Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 75. Intercept Pharmaceuticals Corporate Summary

Table 76. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings

Table 77. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 78. Shire Plc Corporate Summary

Table 79. Shire Plc Primary Sclerosing Cholangitis Treatment Product Offerings

Table 80. Shire Plc Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 81. NGM Biopharmaceuticals Corporate Summary

Table 82. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings

Table 83. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 84. Conatus Pharmaceuticals Corporate Summary

Table 85. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings

Table 86. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 87. Durect Corporation Corporate Summary

Table 88. Durect Corporation Primary Sclerosing Cholangitis Treatment Product Offerings

Table 89. Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 90. Sirnaomics Corporate Summary

Table 91. Sirnaomics Primary Sclerosing Cholangitis Treatment Product Offerings

Table 92. Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue (US\$, Mn), (2017-2022)

Table 93. Shenzhen HighTide Biopharmaceuticals Corporate Summary

Table 94. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings

Table 95. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis

Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Primary Sclerosing Cholangitis Treatment Segment by Type in 2021
- Figure 2. Primary Sclerosing Cholangitis Treatment Segment by Application in 2021
- Figure 3. Global Primary Sclerosing Cholangitis Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Primary Sclerosing Cholangitis Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2021
- Figure 8. By Type - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
- Figure 12. US Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028

Figure 24. China Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Primary Sclerosing Cholangitis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Allergan Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Glenmark Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Mylan Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Lannett Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Bruschettini Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Grindeks Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Shire Plc Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 55. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 57. Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 58. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Primary Sclerosing Cholangitis Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/PD7DA25A8924EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD7DA25A8924EN.html>